Global Travel Vaccines Market Size Study, by Type, by Disease, and Regional Forecasts 2024-2032

Global Travel Vaccines Market is valued at approximately USD 8.26 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 10.06% over the forecast period 2024-2032. Travel vaccines are essential immunizations recommended or required for international travelers based on specific regional disease risks. These vaccines play a crucial role in preventing diseases that may be prevalent in certain parts of the world, thus safeguarding travelers' health and contributing to global public health efforts. The continuous growth in international travel, coupled with rising awareness about vaccine-preventable diseases, fuels the demand for travel vaccines. Governmental travel regulations mandating certain vaccines for entry further bolster the market. The global tourism industry's expansion and proactive health measures by travelers also drive the need for travel vaccines. Furthermore, advancements in vaccine storage and stability technologies enhance accessibility and distribution, contributing significantly to market growth.

Despite the promising growth, the travel vaccines market faces several challenges, including high costs associated with vaccine development and stringent regulatory requirements, which can lead to prolonged approval times. Additionally, the limited shelf life of vaccines, the need for cold chain logistics, and vaccine hesitancy among certain traveler demographics can impede market growth. However, developing vaccines against emerging infectious disease threats and expanding the travel vaccine portfolio to include neglected tropical diseases present substantial opportunities. Increased public-private partnerships for vaccine research and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders further enhance market prospects.

The cryopreserved amniotic membrane segment is witnessing significant growth due to its live cell therapy applications. The cryopreserved amniotic membrane is preserved at subzero temperatures, maintaining its biological properties and structural integrity. This preservation method ensures the tissue's therapeutic effectiveness, allowing for long-term storage and availability for various clinical applications. Similarly, lyophilization amniotic membranes, produced by freeze-drying the tissue, offer stability at room temperature, facilitating easy storage and distribution.

In terms of application, the use of amniotic membranes in ophthalmology is highly recognized for treating complex ocular surface diseases. Their therapeutic properties, including promoting surface reconstruction and reducing inflammation, make them essential in corneal surgeries. Amniotic membranes also serve as biological dressings in surgical wound care, assisting with the natural healing process in burns, chronic wounds, and surgical incisions. Specialized clinics utilize these membranes for targeted treatments in dental, ophthalmology, and dermatology practices.

The hospital segment is a significant end-user of amniotic membranes, utilizing them in various surgical procedures to leverage their regenerative properties. Ambulatory Surgical Centers (ASCs) also implement amniotic membrane transplants, particularly in ophthalmology, wound care, and reconstructive surgery. Research centers and laboratories focus on exploring novel uses and enhancing the medical understanding of amniotic membranes, primarily studying their biocompatibility, preservation methods, and therapeutic potential.

The key regions considered for the global Travel Vaccines Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Travel Vaccines Market in terms of revenue. The market growth in the region is being attributed to factors including increasing travel and healthcare investments, high outbound travel rates and robust healthcare infrastructure in the United States and Canada. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising investments in smart technologies and extensive vaccine research and development.

Major market players included in this report are:

• Abbott Laboratories
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bharat Biotech Ltd.
• Bio-Manguinhos
• Bio-Med (P) Limited
• Biological E Limited
• Cadila Pharmaceuticals Limited
• CSL Limited
• Dano Vaccines & Biologicals Private Limited
• Dynavax Technologies Corporation
• Emergent BioSolutions Inc.
• GlaxoSmithKline PLC
• Incepta Pharmaceuticals Ltd.
• Indian Immunologicals Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type:

• Attenuated Vaccines
• Conjugate Vaccines
• DNA Vaccines
• Inactive Vaccines
• Recombinant Vector Vaccines
• Subunit Vaccines
• Toxoid Vaccines

By Disease:

• DPT
• Hepatitis A
• Hepatitis B
• Japanese Encephalitis
• Measles and Mumps
• Meningococcal
• Rabies
• Typhoid
• Varicella
• Yellow Fever

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.